Treatment should be deferred in patients at risk for developing immune reconstitution inflammatory syndrome (IRIS), which is possible in treatment naïve patients, presenting with opportunistic infections and a low CD4 count (< 50 cells/μL) (NDoH 2019). The gene discussed is CD4; the disease is Opportunistic infection.